Colonic mucosal interleukin 1 receptor antagonist in inflammatory bowel disease
- PMID: 7705549
- DOI: 10.1159/000201167
Colonic mucosal interleukin 1 receptor antagonist in inflammatory bowel disease
Abstract
To clarify the role of the interleukin 1 receptor antagonist (IL-1ra) in patients with inflammatory bowel disease (IBD), we assessed the local IL-1ra concentrations in tissue homogenates using a specific enzyme-linked immunosorbent assay and examined the immunohistochemical localization using a monoclonal antibody against IL-1ra. In patients with IBD, regardless of the disease activity, the mucosal concentration of IL-1ra in affected areas was elevated, and the concentration during the active phase was comparable to that measured during the inactive phase. In contrast, the IL-1 beta tissue concentration was higher during the active than during the inactive phase. The IL-1ra/IL-1 beta tissue concentration ratio in the affected areas was decreased in patients with active IBD as compared with normal controls or patients with other types of colitis. Immunohistochemical studies identified lamina propria mononuclear cells, especially macrophages, as the major source of IL-1ra in IBD tissue. Our results suggest that IL-1ra plays a pivotal role in regulating inflammation in IBD.
Similar articles
-
Imbalance of the interleukin 1 system in colonic mucosa--association with intestinal inflammation and interleukin 1 receptor antagonist [corrected] genotype 2.Gut. 1997 Nov;41(5):651-7. doi: 10.1136/gut.41.5.651. Gut. 1997. PMID: 9414973 Free PMC article.
-
Relationship of interleukin-1 receptor antagonist to mucosal inflammation in inflammatory bowel disease.J Pediatr Gastroenterol Nutr. 1995 Nov;21(4):419-25. doi: 10.1097/00005176-199511000-00008. J Pediatr Gastroenterol Nutr. 1995. PMID: 8583293
-
Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation.J Immunol. 1995 Mar 1;154(5):2434-40. J Immunol. 1995. PMID: 7868909 Clinical Trial.
-
Interleukin-1 and interleukin-1 receptor antagonist in inflammatory bowel disease.Aliment Pharmacol Ther. 1996;10 Suppl 2:49-53; discussion 54. doi: 10.1046/j.1365-2036.1996.22164020.x. Aliment Pharmacol Ther. 1996. PMID: 8899101 Review.
-
Cytokine profiles differ in newly recruited and resident subsets of mucosal macrophages from inflammatory bowel disease.Gastroenterology. 1997 May;112(5):1493-505. doi: 10.1016/s0016-5085(97)70030-1. Gastroenterology. 1997. PMID: 9136827 Review.
Cited by
-
Opposing Functions of Classic and Novel IL-1 Family Members in Gut Health and Disease.Front Immunol. 2013 Jul 9;4:181. doi: 10.3389/fimmu.2013.00181. eCollection 2013. Front Immunol. 2013. PMID: 23847622 Free PMC article.
-
Colonic explant production of IL-1and its receptor antagonist is imbalanced in inflammatory bowel disease (IBD).Clin Exp Immunol. 1998 Jun;112(3):435-42. doi: 10.1046/j.1365-2249.1998.00595.x. Clin Exp Immunol. 1998. PMID: 9649212 Free PMC article.
-
Emerging role of the interleukin (IL)-33/ST2 axis in gut mucosal wound healing and fibrosis.Fibrogenesis Tissue Repair. 2012 Oct 14;5(1):18. doi: 10.1186/1755-1536-5-18. Fibrogenesis Tissue Repair. 2012. PMID: 23062310 Free PMC article.
-
Interleukin-10 in the pathophysiology of inflammatory bowel disease: increased serum concentrations during the recovery phase.Mediators Inflamm. 2006;2006(6):26875. doi: 10.1155/MI/2006/26875. Mediators Inflamm. 2006. PMID: 17392581 Free PMC article.
-
Novel cytokine signaling pathways in inflammatory bowel disease: insight into the dichotomous functions of IL-33 during chronic intestinal inflammation.Therap Adv Gastroenterol. 2011 Sep;4(5):311-23. doi: 10.1177/1756283X11410770. Therap Adv Gastroenterol. 2011. PMID: 21922030 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources